CRISPR Therapeutics AG (CRSP)

NasdaqGM • Currently down 0.70 (-1.24%) in today's trading session

2 members of Congress have disclosed 5 trades in CRISPR Therapeutics AG (CRSP) via STOCK Act filings. The most recent disclosure was a sale by Thomas R. Suozzi on 20 September 2021. The most active traders have been Thomas R. Suozzi (4) and Marjorie Taylor Greene (1). Aggregate disclosed activity totals roughly $158K in purchases and $107.5K in sales (midpoint estimates from bracketed disclosure amounts).

CRISPR Therapeutics AG is currently trading at $55.79, positioned at 34% of its 52-week range ($44.12 – $78.48).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Claim Free AssetCopy Automatically with eToro

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Past Performance is not an indication of future results.

Current Price
$55.79
24h Change
-0.70 (-1.24%)
52 Week Range
$44.12–$78.48
View on NASDAQ

CRISPR Therapeutics AG Price History and Technical Analysis

Interactive Chart

Congressional Trading Activity for CRSP

Select to highlight on chart
5 transactions
Compliance: 60%
Thomas R. Suozzi20 Sept 20215 Oct 2021SaleStock$50,001 - $100,000N/A
Thomas R. Suozzi20 Sept 202119 Dec 2022SaleStock$15,001 - $50,000N/A
Thomas R. Suozzi3 Jun 202123 Sept 2021PurchaseStock$50,001 - $100,000N/A
Thomas R. Suozzi3 Jun 202119 Dec 2022PurchaseStock$50,001 - $100,000N/A
Marjorie Taylor Greene21 Jan 202119 Feb 2021PurchaseStock$1,001 - $15,000N/A

Select transactions to view their annotations on the chart

Stock Overview

Market Data

Market Cap

$5.38B

Volume

904.29K

Beta

1.76

P/E Ratio

-11.72

Fundamentals

EPS

$-4.76

Div. Yield

-

Open

$56.06

Day Range

$55.35 – $57.12

Company Information

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ · USD
Country
CH
CEO
Samarth Kulkarni
IPO Date
2016-10-19
Website
www.crisprtx.com

CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associat...

Earnings

Next Report

Q3 2026

9 Nov

EPS Est.

$-1.06

Rev. Est.

$14.8M

Days Until

63

Recent Quarters

Q2 20263 Aug
EPS$-0.94
Beat 21.0%
Q1 20264 May
EPS$-1.28
Miss 7.6%
Q4 202512 Feb
EPS$-1.37
Miss 19.1%
Q3 202510 Nov
EPS$-1.17
Beat 7.1%
Q2 20255 Aug
EPS$-2.40
Miss 63.3%
Q1 20256 May
EPS$-1.58
Miss 24.4%
Q4 202411 Feb
EPS$-0.44
Beat 61.7%
Q3 20245 Nov
EPS$-1.01
Beat 24.1%
Q2 20245 Aug
EPS$-1.49
Miss 8.8%
Q1 20248 May
EPS$-1.43
Beat 12.3%
Q4 202321 Feb
EPS$1.10
Beat 1671.4%
Q3 20236 Nov
EPS$-1.41
Beat 28.8%
Q2 20237 Aug
EPS$-0.98
Beat 55.0%
Q1 20238 May
EPS$-0.67
Beat 59.9%
Q4 202221 Feb
EPS$-1.41
Beat 39.2%
Q3 20221 Nov
EPS$-2.24
Beat 2.6%
Q2 20228 Aug
EPS$-2.40
Miss 7.6%
Q1 20229 May
EPS$-2.32
Miss 21.5%
Q4 202115 Feb
EPS$-1.84
Miss 5.8%
Q3 20213 Nov
EPS$-1.67
Beat 1.2%
Q2 202129 Jul
EPS$9.44
Beat 168.2%
Q1 202127 Apr
EPS$-1.51
Miss 4.1%
Q4 202016 Feb
EPS$-1.50
Miss 21.9%
Q3 202028 Oct
EPS$-1.32
Miss 12.8%
Q2 202027 Jul
EPS$-1.30
Miss 41.3%
Q1 202028 Apr
EPS$-1.15
Miss 5.5%
Q4 201912 Feb
EPS$0.51
Beat 180.9%
Q3 201928 Oct
EPS$2.40
Beat 352.6%
Q2 201929 Jul
EPS$-1.01
Miss 24.7%
Q1 201929 Apr
EPS$-0.93
Miss 5.7%
Q4 201825 Feb
EPS$-0.92
Miss 10.8%
Q3 20187 Nov
EPS$-1.07
Miss 44.6%
Q2 20187 Aug
EPS$-0.82
Miss 26.1%
Q1 20188 May
EPS$-0.62
Beat 7.5%
Q4 20178 Mar
EPS$0.00
Beat 100.5%
Q3 20178 Nov
EPS$-0.62
Miss 3.3%
Q2 201710 Aug
EPS$-0.56
Beat 9.7%
Q1 201711 May
EPS$-0.54
Miss 5.9%
Q4 201610 Mar
EPS$-0.40
Miss 5.3%
Q3 201622 Nov
EPS$-2.77
Miss 284.7%
Q3 201619 Oct
EPS$-0.43
Q4 201531 Mar
EPS$-0.29
Q3 201531 Dec
EPS$-0.42
Q2 201530 Sept
EPS$-0.22
Q1 201530 Jun
EPS$-0.66
Q4 201431 Mar
EPS$-0.91

1 politician traded within 30 days

No dividend data available for this stock.

No stock split data available for this stock.

Similar Stocks

Based on congressional trading patterns

Smart Recommendations

AMD

Advanced Micro Devices, Inc.

20
$477.57+21.41 (+4.69%)
Technology
Held by same politician
Significant holdings value
1 politician
View Stock

INTC

Intel Corporation

20
$95.80+4.13 (+4.51%)
Technology
Held by same politician
Significant holdings value
1 politician
View Stock

CAT

Caterpillar Inc.

17
$813.94+13.80 (+1.72%)
Industrials
Held by same politician
1 politician
View Stock

Frequently Asked Questions about CRSP

Which members of Congress have traded CRSP?
2 members of Congress have disclosed 5 trades in CRISPR Therapeutics AG (CRSP) under the STOCK Act. The most active traders are Thomas R. Suozzi and Marjorie Taylor Greene.
When was CRSP most recently disclosed by Congress?
The most recent CRSP disclosure was a sale by Thomas R. Suozzi on 20 September 2021.
What is the total disclosed congressional trading volume for CRSP?
Members of Congress have disclosed approximately $158K in CRSP purchases and $107.5K in sales. These figures are midpoint estimates derived from the bracketed amount ranges used in STOCK Act filings.
How can I track new congressional trades in CRSP?
This CRSP page updates as soon as new STOCK Act disclosures are filed for CRISPR Therapeutics AG. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi Tracker
PoliticiansBillsArticlesPortfoliosPricingAboutLegalTerms of ServicePrivacy Policy
Français
© 2026 - All rights reserved. Powered by Vantara Labs
Pelosi Tracker is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office or her representatives, or with any other member of Congress. Any use of her name is solely for the purpose of discussing publicly available information.The information provided by Pelosi Tracker is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.